1. 149OEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies. (25th November 2018) Authors: Kang, Y-K; Kudo, M; Lim, H-Y; Hsu, C-H; Vogel, A; Brandi, G; Cheng, R; Carton, I; Abada, P; Hsu, Y; Zhu, A; Yen, C-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 151OPractice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions. (25th November 2018) Authors: Heo, J; Cheng, A-L; Raoul, J-L; Peck-Radosavljevic, M; Kudo, M; Nakajima, K; Bayh, I; Lin, S-M; Lee, H C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 153OM7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. (25th November 2018) Authors: Yoo, C; Oh, D-Y; Choi, H J; Kudo, M; Ueno, M; Kondo, S; Chen, L-T; Osada, M; Helwig, C; Dussault, I; Ikeda, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 420 Transcriptome analysis of glassy cell carcinoma and mucinous adenocarcinoma compared with squamous cell carcinoma of uterine cervix. (13th November 2020) Authors: Ishizuka, Y; Hasebe, R; Asano, H; Sakurai, M; Yamazaki, H; Ihira, K; Endo, D; Mitamura, T; Konno, Y; Kato, T; Kudo, M; Watari, H; Murakami, M Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. (23rd October 2018) Authors: Finn, R S; Kudo, M; Cheng, A-L; Wyrwicz, L; Ngan, R; Blanc, J F; Baron, A D; Vogel, A; Ikeda, M; Piscaglia, F; Han, K-H; Qin, S; Minoshima, Y; Kanekiyo, M; Ren, M; Dairiki, R; Tamai, T; Dutcus, C E; Funahashi, Y; Evans, T R J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 622PDRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). (23rd October 2018) Authors: Zhu, A X; Finn, R S; Galle, P R; Llovet, J M; Blanc, J F; Okusaka, T; Chau, I; Cella, D; Girvan, A; Gable, J; Bowman, L; Hsu, Y; Abada, P B; Kudo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 697PA phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. (23rd October 2018) Authors: Cheng, A-L; Yen, C-J; Okusaka, T; Ikeda, M; Hsu, C-H; Wu, S-Y; Morizane, C; Hashimoto, Y; Ueshima, K; Ohtomo, T; Tanaka, T; Kudo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 757PM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. (23rd October 2018) Authors: Yoo, C; Oh, D-Y; Choi, H J; Kudo, M; Ueno, M; Kondo, S; Chen, L-T; Osada, M; Helwig, C; Dussault, I; Ikeda, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 776TiPGlobal phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress. (23rd October 2018) Authors: Qin, S; Finn, R S; Kudo, M; Meyer, T; Vogel, A; Ducreux, M P; Macarulla, T M; Tomasello, G; Boisserie, F; Hou, J; Li, C; Song, J; Zhu, A X Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Author response to: Comment on: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Issue 4 (4th March 2020) Authors: Aoki, T; Kubota, K; Kubo, S; Kudo, M Journal: British journal of surgery Issue: Volume 107:Issue 4(2020) Page Start: 470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗